MedTrace Logo

Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)

NCT04824950 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2021-04-01

No results posted yet for this study

Summary

The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of obtaining a metabolic complete response after 4 cycles of induction chemotherapy (C4) in patients with primary mediastinal large B cell lymphoma (PMBL) receiving standard R-CHOP14 or R-ACVBP.

Conditions

  • Primary Mediastinal Large B-cell Lymphoma

Interventions

OTHER

Circulating tumor DNA monitoring

Monitoring of circulating tumor DNA after 2 and 4 cycles of chemotherapy

Sponsors & Collaborators

  • Centre Henri Becquerel

    lead OTHER

Principal Investigators

  • VINCENT CAMUS, MD · Centre Henri Becquerel

  • PIERRE SESQUES, MD · Centre Hospitalier Lyon Sud

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-22
Primary Completion
2028-03-01
Completion
2028-03-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04824950 on ClinicalTrials.gov